<SEC-DOCUMENT>0001096906-23-000240.txt : 20230131
<SEC-HEADER>0001096906-23-000240.hdr.sgml : 20230131
<ACCEPTANCE-DATETIME>20230131162347
ACCESSION NUMBER:		0001096906-23-000240
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230131
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230131
DATE AS OF CHANGE:		20230131

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		23572871

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>utmd-20230131.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='us-ascii' standalone='no'?>
<html xmlns='http://www.w3.org/1999/xhtml' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:dei='http://xbrl.sec.gov/dei/2022' xmlns:i='http://www.xbrl.org/2003/instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:iso4217='http://www.xbrl.org/2003/iso4217' xmlns:ix='http://www.xbrl.org/2013/inlineXBRL' xmlns:ixt='http://www.xbrl.org/inlineXBRL/transformation/2015-02-26' xmlns:ixt-sec='http://www.sec.gov/inlineXBRL/transformation/2015-08-31' xmlns:utr='http://www.xbrl.org/2009/utr' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance'>
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK5GW761L0VGXA5UT0]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing</title>
<meta content='text/html; charset=UTF-8' http-equiv='Content-Type' />
</head>
<body>
<div style='display:none'>
<ix:header>
<ix:hidden>
<ix:nonNumeric name='dei:EntityCentralIndexKey' contextRef='D230131' id='fact1'>0000706698</ix:nonNumeric>
<ix:nonNumeric name='dei:AmendmentFlag' contextRef='D230131' id='fact2'>false</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole='http://www.xbrl.org/2003/linkbase' xlink:href='utmd-20230131.xsd' xlink:type='simple'/>
</ix:references>
<ix:resources>
<i:context id='D230131'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2023-01-31</i:startDate>
<i:endDate>2023-01-31</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style='margin-left:72pt;width:468pt'><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:14pt Times New Roman;margin:0;text-align:center'><b>UNITED STATES </b></p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style='font:15pt Times New Roman;margin:0;text-align:center'><b>Washington, D.C. &#160;20549</b></p>
<p style='font:15pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'><span style='font-size:14pt'><b>FORM </b><b><ix:nonNumeric name='dei:DocumentType' contextRef='D230131' escape='true'>8-K</ix:nonNumeric></b></span></p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'><b>CURRENT REPORT</b></p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:12pt Times New Roman;margin:0;text-align:center'><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>Date of Report (date of earliest event reported): &#160;<b><ix:nonNumeric name='dei:DocumentPeriodEndDate' contextRef='D230131' format='ixt:datemonthdayyearen'>January 31, 2023</ix:nonNumeric></b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;margin-right:72pt;text-align:justify'>&#160;</p>
<table style='border-collapse:collapse;width:468pt'><tr><td colspan='5' valign='top' style='width:468pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:14pt Times New Roman;margin:0;text-align:center'><b><ix:nonNumeric name='dei:EntityRegistrantName' contextRef='D230131' escape='true'>UTAH MEDICAL PRODUCTS, INC.</ix:nonNumeric></b></p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:468pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Exact name of registrant as specified in its charter)</p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:11pt'><b><ix:nonNumeric name='dei:EntityIncorporationStateCountryCode' contextRef='D230131' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric></b></span></p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><b><ix:nonNumeric name='dei:EntityFileNumber' contextRef='D230131' escape='true'>000-12575</ix:nonNumeric></b></p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:11pt'><b><ix:nonNumeric name='dei:EntityTaxIdentificationNumber' contextRef='D230131' escape='true'>87-0342734</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(State or other jurisdiction of</p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Commission File Number)</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(IRS Employer</p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>incorporation or organization)</p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>Identification No.)</p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b><ix:nonNumeric name='dei:EntityAddressAddressLine1' contextRef='D230131' escape='true'>7043 South 300 West</ix:nonNumeric></b></span></p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b><ix:nonNumeric name='dei:EntityAddressCityOrTown' contextRef='D230131' escape='true'>Midvale</ix:nonNumeric></b><b>, </b><b><ix:nonNumeric name='dei:EntityAddressStateOrProvince' contextRef='D230131' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric></b></span></p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b><ix:nonNumeric name='dei:EntityAddressPostalZipCode' contextRef='D230131' escape='true'>84047</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Address of principal executive offices)</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Zip code)</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:11pt Times New Roman;margin:0'>Registrant&#8217;s telephone number, including area code: &#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b>Phone: </b><b>(</b><b><ix:nonNumeric name='dei:CityAreaCode' contextRef='D230131' escape='true'>801</ix:nonNumeric></b><b>) </b><b><ix:nonNumeric name='dei:LocalPhoneNumber' contextRef='D230131' escape='true'>566-1200</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:468pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:12pt Times New Roman;margin:0;text-align:center'><b>n/a</b></p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:468pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Former name or former address, if changed since last report)</p>
</td></tr>
</table>
<p style='font:11pt Times New Roman;margin:0;margin-right:72pt;text-align:justify'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</div>
<div style='margin-left:72pt'><table style='border-collapse:collapse'><tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:WrittenCommunications' contextRef='D230131' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:SolicitingMaterial' contextRef='D230131' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:PreCommencementTenderOffer' contextRef='D230131' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:PreCommencementIssuerTenderOffer' contextRef='D230131' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:478.8pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>Emerging growth company <ix:nonNumeric name='dei:EntityEmergingGrowthCompany' contextRef='D230131' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:478.8pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:478.8pt'><p style='font:10pt Times New Roman;margin:0'>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&#160;&#160;]</p>
</td></tr>
</table>
</div>
<div style='margin-left:72pt;width:468pt'><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><hr style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0'><b>ITEM 2.02&#8212;RESULTS OF OPERATIONS AND FINANCIAL CONDITION</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:90pt'>Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and twelve months ended December 31, 2022 and forward-looking statements relating to 2022 and beyond as presented in a press release dated January 31, 2023. &#160;</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:90pt'>&#160;</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:90pt'>The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:90pt'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0'><b>ITEM 9.01&#8212;FINANCIAL STATEMENTS AND EXHIBITS</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>The following is filed as an exhibit to this report: &#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</div>
<div style='margin-left:72pt'><table style='border-collapse:collapse;width:476pt'><tr><td valign='top' style='width:59.75pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Exhibit</b></p>
<p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Number*</b></p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:329.5pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Title of Document</b></p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:61.75pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Location</b></p>
</td></tr>
<tr><td valign='top' style='width:59.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><b>Item 99.1</b></p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:329.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'><span style='font-size:12pt'>Financial information for Utah Medical Products, Inc. for the three and twelve months ended December 31, 2022 and forward-looking statements relating to 2022 and beyond as presented in a press release dated January 31, 2023.</span></p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:61.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:59.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:329.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:61.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>This filing</p>
</td></tr>
<tr><td valign='top' style='width:59.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:329.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:61.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
</table>
</div>
<div style='margin-left:72pt;width:468pt'><p style='font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify'>_______________________________________</p>
<p style='font:9pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:18pt;text-align:justify'><kbd style='position:absolute;font:9pt Times New Roman;margin-left:-18pt'>*</kbd>All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document. &#160;</p>
<p style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-indent:-18pt;margin-left:18pt;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'><b>SIGNATURES</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</div>
<div style='margin-left:72pt'><table style='border-collapse:collapse'><tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'><b>UTAH MEDICAL PRODUCTS, INC.</b></p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>Dated:  January 31, 2023</p>
</td><td valign='top' style='width:26.7pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>By:</p>
</td><td valign='top' style='width:218.05pt;border-bottom:0.5pt solid #000000'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>/s/ Kevin L. Cornwell</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:26.7pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:218.05pt;border-top:0.5pt solid #000000'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>Kevin L. Cornwell, Chief Executive Officer</p>
</td></tr>
</table>
</div>
<div style='margin-left:72pt;width:468pt'><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/></div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>utmd_ex99z1.htm
<DESCRIPTION>FINANCIAL INFORMATION
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK5GW761L0VGXA5UT0]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style=font-size:11pt><B>EXHIBIT 99.1</B></FONT><B> </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'><B>UTMD Reports Audited Year 2022 and Fourth Quarter Financial Performance</B></P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:0pt'>Contact: Brian Koopman (801) 566-1200</KBD><KBD style=margin-left:360pt></KBD>January 31, 2023&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Salt Lake City, Utah &#8211;&nbsp;Utah Medical Products, Inc. (Nasdaq: UTMD) finished the calendar year with a solid fourth quarter (4Q) performance, which allowed financial results for the year 2022 exceeding management&#8217;s beginning of year projections, despite many challenges. &nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&nbsp;or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&nbsp;or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Overview of Results</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>A summary comparison of 4Q and calendar year 2022 income statement measures with the same periods of 2021 follows:</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:198pt'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4Q</KBD><KBD style=margin-left:270pt></KBD> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2022 to 2021 Comparison</FONT> &nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>(October&#8211;December)</FONT> &nbsp;&nbsp;&nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>(January-December)</FONT></P>
<TABLE style=border-collapse:collapse;width:499.5pt;margin-left:27.9pt><TR><TD valign=top style=width:166.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Revenues (Sales):</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt Times New Roman;margin:0;text-indent:30.6pt;margin-right:-6.3pt'>+ &nbsp;&nbsp;&nbsp;&nbsp;5%</P>
</TD><TD valign=top style=width:99pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>+ &nbsp;&nbsp;&nbsp;&nbsp;7%</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt Times New Roman;margin:0;text-indent:17.1pt;margin-right:-6.3pt'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:166.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit (GP):</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt Times New Roman;margin:0;text-indent:30.6pt;margin-right:-6.3pt'>+ &nbsp;&nbsp;&nbsp;&nbsp;3%</P>
</TD><TD valign=top style=width:99pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>+ &nbsp;&nbsp;&nbsp;&nbsp;4%</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt Times New Roman;margin:0;text-indent:17.1pt;margin-right:-6.3pt'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:166.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income (OI):</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt Times New Roman;margin:0;text-indent:30.6pt;margin-right:-6.3pt'> &nbsp;  &nbsp;&nbsp;(1%) </P>
</TD><TD valign=top style=width:99pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>+ &nbsp;&nbsp;&nbsp;&nbsp;5% </P>
</TD><TD valign=top style=width:117pt><P style='font:11pt Times New Roman;margin:0;text-indent:17.1pt;margin-right:-6.3pt'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:166.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Income Before Tax (EBT):</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income (NI):</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt Times New Roman;margin:0;text-indent:30.6pt;margin-right:-6.3pt'>+ &nbsp;&nbsp;&nbsp;&nbsp;8% </P>
<P style='font:11pt Times New Roman;margin:0;text-indent:30.6pt;margin-right:-6.3pt'>+ &nbsp;&nbsp;10%</P>
</TD><TD valign=top style=width:99pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>+ &nbsp;&nbsp;&nbsp;&nbsp;8% </P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>+ &nbsp;&nbsp;11%</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt Times New Roman;margin:0;text-indent:17.1pt;margin-right:-6.3pt'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:166.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Earnings Per Share (EPS):</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:6pt;text-indent:30.6pt;margin-right:-6.5pt'>+ &nbsp;&nbsp;11%</P>
</TD><TD valign=top style=width:99pt><P style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:6pt;margin-right:-6.5pt'>+ &nbsp;&nbsp;12%</P>
</TD><TD valign=top style=width:117pt><P style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:6pt;text-indent:17.1pt;margin-right:-6.5pt'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Sales invoiced in foreign currencies, which represented 25% of total consolidated sales (when expressed in USD) during 2022, were substantially diminished by a stronger USD. &nbsp;Using the same foreign currency exchange (FX) rates as in the prior year (&#8220;constant currency&#8221; sales), revenues in 4Q 2022 were up 9%, and for the 2022 year were up almost 10%.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Profit margins in 4Q and year 2022 compared to 4Q and year 2021 follow:</P>
<TABLE style=border-collapse:collapse;width:502.1pt;margin-left:-1.7pt><TR><TD valign=top style=width:232.1pt><P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>4Q 2022 </P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'><FONT style='border-bottom:1px solid #000000'>(Oct &#8211;&nbsp;Dec)</FONT></P>
</TD><TD valign=top style='width:76.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'>4Q 2021</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(Oct-Dec)</FONT></P>
</TD><TD valign=top style='width:66.7pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'>2022</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(Jan&#8211;Dec)</FONT></P>
</TD><TD valign=top style=width:59.3pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'>2021</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(Jan&#8211;Dec)</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:232.1pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit Margin (GP/ sales):</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>61.3%</P>
</TD><TD valign=top style='width:76.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>62.8% </P>
</TD><TD valign=top style='width:66.7pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>61.6%</P>
</TD><TD valign=top style=width:59.3pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>63.0%</P>
</TD></TR>
<TR><TD valign=top style=width:232.1pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income Margin (OI/ sales):</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>37.3%</P>
</TD><TD valign=top style='width:76.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>39.7%</P>
</TD><TD valign=top style='width:66.7pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>37.9%</P>
</TD><TD valign=top style=width:59.3pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>38.5%</P>
</TD></TR>
<TR><TD valign=top style=width:232.1pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Income Before Tax Margin (EBT/ sales):</P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>41.2%</P>
</TD><TD valign=top style='width:76.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>40.1%</P>
</TD><TD valign=top style='width:66.7pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>39.5%</P>
</TD><TD valign=top style=width:59.3pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>38.9%</P>
</TD></TR>
<TR><TD valign=top style=width:232.1pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income Margin &nbsp;(US GAAP)&#185;:</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'><I>Net Income Margin (Non-US GAAP)&#178;:</I></P>
</TD><TD valign=top style=width:67.5pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>33.6%</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'><I>33.6% </I></P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'><B>32.0%</B></P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'><B><I>32.0%</I></B></P>
</TD><TD valign=top style=width:66.7pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>31.5%</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'><I>31.5%</I></P>
</TD><TD valign=top style=width:59.3pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>30.1%</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'><I>30.9%</I></P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&#185; The Net Income Margin is NI (after subtracting a provision for income taxes) divided by sales.</P>
<P style='font:11pt Times New Roman;margin:0'>&#178; A deferred tax liability (DTL) adjustment occurred in 2Q 2021 that is the difference in US GAAP and &nbsp;&nbsp;&nbsp;Non-US GAAP annual Net Income Margin. Please see the explanation below. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-right:-6.5pt'>UTMD&#8217;s GP Margin (GPM) was primarily diluted from proportionately greater variable manufacturing costs, including raw materials, incoming freight, sterilization and direct labor, than UTMD&#8217;s price increases for goods sold to customers. &nbsp;UTMD&#8217;s OI Margin, in addition to incorporating the lower GPM, was impacted by substantial legal costs which did not occur in the prior year. &nbsp;The EBT Margin, on the other hand, benefitted from Non-operating Income from higher interest earned on higher cash balances. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-right:-6.5pt'>The above annual changes in NI and EPS according to U.S. Generally Accepted Accounting Principles (US GAAP) reflects an unfavorable 2Q 2021 adjustment to UTMD&#8217;s long term DTL. The 2021 DTL adjustment increased the balance of Femcare identifiable intangible assets (IIA) which will be amortized through 1Q 2026. According to US GAAP, the future income tax impact of a change in DTL must be recognized in the tax provision of the calendar quarter in which a tax law change is enacted. In 2Q 2021, a $390 increase in the DTL over the remaining five years of Femcare IIA amortization occurred because in </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-right:-6.5pt'><FONT style=font-size:11pt>June 2021, UK parliament ratified the Finance Minister&#8217;s plan to increase the UK corporate income tax rate from 19% to 25% beginning on April 1, 2023, which affects deferred taxes for IIA to be amortized after April 1, 2023 until fully amortized as of 1Q 2026. (As stockholders may remember, the DTL was initiated as of the 2011 acquisition of Femcare because the expense from amortizing Femcare IIA, most of which is occurring over a fifteen year time span from the acquisition date, is not tax-deductible in the UK.) </FONT></P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:6pt;margin-right:-6.5pt'>UTMD management believes that the presentation of income statement results excluding the DTL adjustment in 2021 provides meaningful supplemental information to both management and investors that is more clearly indicative of UTMD&#8217;s year-to-year comparative operating results. The non-GAAP exclusion only affects the year-to-year comparison, resulting in a more conservative increase in Net Income and Earnings Per Share.</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Excluding the 2Q 2021 DTL increase due to a UK corporate income tax rate change starting in 2023, the resulting comparison of non-US GAAP NI and EPS changes follows: </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><KBD style=margin-left:144pt></KBD><FONT style='border-bottom:1px solid #000000'>Year 2022 to Year 2021</FONT>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:408.2pt;margin-left:18.9pt><TR><TD valign=top style=width:139.5pt><P style='font:11pt Times New Roman;margin:0;margin-left:-5.4pt;margin-right:-6.3pt'>NI (non-US GAAP):</P>
</TD><TD valign=top style=width:94.5pt><P style='font:11pt Times New Roman;margin:0;text-indent:-5.4pt;margin-right:-6.3pt'>+ &nbsp;9%</P>
</TD><TD valign=top style=width:174.2pt><P style='font:11pt Times New Roman;margin:0;text-indent:-9.35pt;margin-right:-6.3pt'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:139.5pt><P style='font:11pt Times New Roman;margin:0;margin-left:-5.4pt;margin-right:-6.3pt'>EPS (non-US GAAP):</P>
</TD><TD valign=top style=width:94.5pt><P style='font:11pt Times New Roman;margin:0;text-indent:-5.4pt;margin-right:-6.3pt'>+ &nbsp;9%</P>
</TD><TD valign=top style=width:174.2pt><P style='font:11pt Times New Roman;margin:0;text-indent:-5.4pt;margin-right:-6.5pt'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>In other words, excluding the income tax provision adjustment which resulted from the DTL change in 2Q 2021, the comparison of annual increases in Net Income and EPS were similar to the improvement in Income Before Taxes (EBT). &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s December 31, 2022 Balance Sheet, in the continued absence of debt, further strengthened. After using $2,495 cash to repurchase UTMD stock, $3,163 cash to pay stockholder dividends and $809 for new manufacturing equipment and tooling during 2022, ending Cash and Investments were $75.1 million on December 31, 2022 compared to $61.0 million on December 31, 2021. In addition, in order to hedge against ongoing supply chain disruption, UTMD used its cash trove to increase inventories $2.2 million, a 34% increase from the end of 2021. Stockholders&#8217; Equity (SE) increased $7.1 million as of December 31, 2022 from December 31, 2021 despite the fact that the $5.7 in stock repurchases and stockholder dividends reduced SE. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Foreign currency exchange (FX) rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of calendar year 2022 compared to the end of 2021 and the end of 3Q 2022 follow:</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>12-31-22</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>12-31-21</FONT></P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9-30-22</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'>1.20771</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>1.35358</P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(10.8%)</P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1.11303</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'> 8.5%</P>
</TD></TR>
<TR><TD valign=top style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'>1.06940</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>1.13765</P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;6.0%)</P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>0.97878</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'> 9.3%</P>
</TD></TR>
<TR><TD valign=top style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'>0.68050</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>0.72678</P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;6.4%)</P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>0.64366</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'> 5.7%</P>
</TD></TR>
<TR><TD valign=top style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'>0.73899</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>0.79016</P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;6.5%)</P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>0.72722</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'> 1.6%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Revenues (sales)</FONT> - <FONT style='border-bottom:1px solid #000000'>4Q 2022</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 4Q 2022 UTMD worldwide (WW) sales were $661 (+5.1%) higher than in 4Q 2021. Total constant currency sales were $1,132 (+8.8%) higher. U.S. domestic sales were 7% lower and outside the U.S. (OUS) sales were 25% higher than in 4Q 2021.  &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Domestic U.S. sales in 4Q 2022 were $7,542 compared to $8,104 in 4Q 2021. &nbsp;Domestic sales are invoiced in USD and are not subject to FX rate fluctuations. The components of domestic sales include 1) &#8220;direct other device sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;direct Filshie device sales&#8221;. UTMD separates Filshie device sales from other medical device sales direct to medical facilities because of their significance, and the acquisition history. Direct non-Filshie device sales, representing 50% of total domestic sales, were $354 (9%) lower in 4Q 2022 than in 4Q 2021. The decrease was due in part from UTMD&#8217;s contract sterilizer being unable to complete its committed year-end processing on schedule, delaying shipments into 1Q 2023. &nbsp;OEM sales, representing 33% of total </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style=font-size:11pt>domestic sales, were $36 (1%) lower due to supply chain disruption which postponed delivery of needed raw materials. Direct Filshie device sales, representing 17% of total domestic sales, were $172 (12%) lower in 4Q 2022 compared to 4Q 2021. &nbsp;The medical trend post C-section to perform a salpingectomy/ oophorectomy (removal of Fallopian tubes and/or ovaries) instead of tubal ligation in the U.S. continued.</FONT></P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OUS sales in 4Q 2022 were $6,033 compared to $4,809 in 4Q 2021. An extra $564 shipment for DPT kits occurred in 4Q 2022 to UTMD&#8217;s China distributor, which shipment had been scheduled to ship in &nbsp;3Q 2022, but was delayed due to contract sterilizer capacity constraints in Ireland. &nbsp;Disregarding the negative FX rates impact, OUS sales in 4Q 2022 were up 35% compared to 4Q 2021. This is evidence that results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>For clarity, 4Q 2022 USD-denominated OUS sales compared to 4Q 2021 OUS sales were $471 lower as a result of a stronger USD which reduced OUS net sales that were invoiced in GBP, EUR, AUD and CAD foreign currencies (in constant currency terms). &nbsp;&#8220;Constant currency&#8221; sales means exchanging foreign currency sales into USD-denominated sales at the same FX rate as was in the previous period of time being compared. FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 4Q 2022 and 4Q 2021 for revenue purposes follow:</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'>4<FONT style='border-bottom:1px solid #000000'>Q 2022</FONT></KBD><KBD style=margin-left:248.1pt></KBD>4<FONT style='border-bottom:1px solid #000000'>Q 2021</FONT> &nbsp;&nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>Change</FONT>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>GBP</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 1.1788</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 1.3482</KBD><KBD style=margin-left:297.7pt></KBD>( 12.6%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>EUR</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 1.0192</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 1.1494</KBD><KBD style=margin-left:297.7pt></KBD>( 11.3%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>AUD</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 0.6530</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 0.7306</KBD><KBD style=margin-left:297.7pt></KBD>( 10.6%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>CAD</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 0.7361</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 0.7946</KBD><KBD style=margin-left:297.7pt></KBD>( &nbsp;&nbsp;7.4%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The combined weighted-average negative FX impact was (11.2%). &nbsp;The portion of OUS sales invoiced in foreign currencies in USD terms were 27% of total consolidated 4Q 2022 sales compared to 26% in 4Q 2021. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OUS sales invoiced in foreign currencies are due to direct end-user sales in Ireland, the UK, France, Canada, Australia and New Zealand, and to shipments to OUS distributors of products manufactured by UTMD subsidiaries in Ireland and the UK. &nbsp;In USD terms, export sales to OUS distributors from Ireland represented 71% of total OUS distributor sales. Export sales from the U.S. to OUS distributors are invoiced in USD. &nbsp;Sales to OUS distributors were 44% higher in 4Q 2022 than in 4Q 2021 due to the extra China shipment and higher Ireland OEM shipments. Direct to end-user OUS shipments are generally invoiced in the applicable local currency. &nbsp;Despite a double-digit percentage decline in most of the OUS FX rates, direct to end-user OUS 4Q 2022 sales in USD terms were only 5% lower in Ireland, 10% higher in Canada, and 17% higher in the UK, but 19% lower in France, than in 4Q 2021. &nbsp;Direct to end-user sales in Australia, which included New Zealand, were 32% lower. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Sales</FONT> -<FONT style='border-bottom:1px solid #000000'>2022 Year</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 2022 UTMD worldwide (WW) USD sales were $3,228 (+6.6%) higher than in 2021. Constant currency sales were $4,661 (+9.5%) higher than in 2021. U.S. domestic sales were 4% higher and OUS USD sales were 10% higher. Without the hindrance of a stronger USD in converting foreign currency sales, OUS sales were 18% higher.  </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Domestic U.S. sales in 2022 were $31,971 compared to $30,659 in 2021. &nbsp;Direct device sales other than Filshie, representing 50% of total domestic sales, were $848 (+6%) higher in 2022 than in 2021, despite the year-end $184 sterilizer delay. OEM sales, representing 34% of total domestic sales, were $1,321 (+14%) higher. Direct Filshie device sales, representing 16% of total domestic sales, were $857 (14%) lower in 2022 compared to 2021. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OUS USD sales in 2022 were 10% higher at $20,310 compared to $18,395 in 2021. The increase in USD-denominated OUS sales was reduced as a result of a stronger USD which subtracted $1,433 in OUS sales invoiced in GBP, EUR, AUD and CAD foreign currencies (compared to constant currency terms). &nbsp;FX </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style=font-size:11pt>rates for income statement purposes are transaction-weighted averages. The weighted-average FX rates from the applicable foreign currency to USD during 2022 and 2021 for revenue purposes follow:</FONT></P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'><FONT style='border-bottom:1px solid #000000'> 2022</FONT></KBD><KBD style=margin-left:248.1pt></KBD><FONT style='border-bottom:1px solid #000000'> 2021</FONT> &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>Change</FONT>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>GBP</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 1.2287</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 1.3760</KBD><KBD style=margin-left:297.7pt></KBD>( 10.7%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>EUR</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 1.0520</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 1.1828</KBD><KBD style=margin-left:297.7pt></KBD>( 11.1%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>AUD</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 0.6932</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 0.7514</KBD><KBD style=margin-left:297.7pt></KBD>( &nbsp;&nbsp;7.7%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>CAD</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 0.7683</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 0.7977</KBD><KBD style=margin-left:297.7pt></KBD>( &nbsp;&nbsp;3.7%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The combined weighted-average unfavorable FX impact on 2022 foreign currency OUS sales was 9.9%, decreasing reported USD sales by $1,433 relative to the same foreign currency sales in 2021. &nbsp;In constant currency terms, OUS sales in 2022 were 18.2% higher than OUS sales in 2021. The portion of OUS sales invoiced in foreign currencies in USD terms was 25% of total consolidated 2022 USD sales compared to 27% in 2021. Including the substantial negative impact of FX rates, direct to end-user OUS 2022 sales in USD terms were the same in Ireland, 6% lower in Canada, 13% lower in France and 15% higher in the UK. Direct to end-user sales in Australia, which included New Zealand, were 26% lower. USD denominated sales to OUS distributors were 21% higher in 2022 than in 2021. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Gross Profit (GP)</FONT> &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>GP results from subtracting the costs of manufacturing, quality assurance and receiving materials from suppliers. UTMD&#8217;s GP was $215 (+2.6%) higher in 4Q 2022 than in 4Q 2021, and $1,280 (+4.1%) higher in calendar year 2022 than in 2021. UTMD increased prices for almost all of its devices at the beginning of 2022, and again in mid-year primarily for OEM customers, but manufacturing costs in Utah, where about 60% of the Company&#8217;s product revenues are manufactured, increased at a rate more than double UTMD&#8217;s average price increases, resulting in a lower overall GPM. U.S. direct labor and raw material costs increased more than 10%, while manufacturing overhead (MOH) costs increased more than 20%. &nbsp;As examples of MOH, the Company experienced an unfavorable year for its self-insured U.S. health care plan, a doubling of freight for incoming materials and significantly more engineering dedicated to process improvements. Managing variable manufacturing costs will continue to be a significant challenge in 2023. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Operating Income (OI)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>OI results from subtracting Operating Expenses (OE) from GP. OI in 4Q 2022 was $5,070 compared to $5,129 in 4Q 2021. &nbsp;The $59 lower 4Q 2022 OI was a decrease of 1.2%. &nbsp;The primary reason for the lower 4Q OI was $261 in 4Q 2022 litigation expenses compared to just $12 in 4Q 2021. &nbsp;Litigation expenses are included in General and Administrative (G&amp;A) expenses. &nbsp;For the year 2022, OI was $19,790 compared to $18,880 in 2021, a 4.8% increase, despite $670 in litigation expenses compared to $22 in 2021.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Without the litigation expense difference, USD OE were almost the same in 4Q 2022 and 4Q 2021 &nbsp;helped by a stronger USD converting OUS OE. &nbsp;For the year, litigation expenses were $670 in 2022 compared to $22 in 2021. &nbsp;Litigation expenses in both years were the result of U.S. product liability litigation which remains in discovery. UTMD must defend its longstanding reputation for providing very safe and effective devices. A stronger USD substantially decreased consolidated USD sales in 2022, but it also helped decrease the USD-denominated OE of UTMD&#8217;s foreign subsidiaries by $118 in 4Q 2022 and $385 in year 2022.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OE are comprised of Sales and Marketing (S&amp;M) expenses, G&amp;A expenses and Product Development (R&amp;D) expenses. The following table summarizes OE in 4Q and year 2022 compared to the same periods in 2021 by OE category:</P>
<TABLE style=border-collapse:collapse><TR><TD valign=bottom style=width:59.4pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OE<BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:54pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>4Q 2022</FONT></P>
</TD><TD valign=bottom style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>4Q 2021</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>2022</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>2021</FONT></P>
</TD><TD valign=bottom style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>S&amp;M:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'>$ 441</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;3.3</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 343</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;2.7</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$  &nbsp;1,507</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;2.9</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ &nbsp; 1,414</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;2.9</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>G&amp;A:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'>2,693</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>19.8</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,499</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>19.3</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp; 10,407</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>19.9</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;10,097</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>20.6</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>R&amp;D:</FONT></P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;123</FONT></P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;0.9</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;141</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.1</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;  &nbsp; &nbsp;493</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;0.9</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 526</FONT></P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.1</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>Total OE:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'>3,257</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>24.0</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,983</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>23.1</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;12,407</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>23.7</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp; 12,037</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>24.6</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The following table summarizes &#8220;constant currency&#8221; OE in 4Q and year 2022 compared to the same periods in 2021 by OE category:</P>
<TABLE style=border-collapse:collapse><TR><TD valign=bottom style=width:59.4pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OE<BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:54pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>4Q 2022<BR><FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>4Q 2021</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>2022<BR><FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-right:0.3pt'><FONT style='border-bottom:1px solid #000000'>2021</FONT></P>
</TD><TD valign=bottom style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>S&amp;M:</P>
</TD><TD valign=top style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 451</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$ 343</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ &nbsp;&nbsp;&nbsp;1,540</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$  &nbsp;&nbsp;1,414</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>G&amp;A:</P>
</TD><TD valign=top style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'>2,801</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>2,499</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;10,757</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp; 10,097</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>R&amp;D:</FONT></P>
</TD><TD valign=top style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;123</FONT></P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;141</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;494</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp; &nbsp; &nbsp; &nbsp;526</FONT></P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>Total OE:</P>
</TD><TD valign=top style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'>3,375</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>2,983</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;12,791</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp; 12,037</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>S&amp;M expenses increased in 2022 primarily because UTMD expanded its warehouse and distribution resources to accommodate storage of finished devices and drop-shipping to end users for its largest OEM customer, in addition to similar marginal labor cost increases as in manufacturing. &nbsp;UTMD also attended more trade shows in 2022, as the year of 2021 was COVID restricted. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>A division of G&amp;A expenses by location follows. Note that between 58% and 65% of total G&amp;A expenses in all periods were from the non-cash expense of amortizing IIA related to the Filshie Clip System. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:447.1pt><TR><TD valign=bottom style=width:89.7pt><P align=center style='font:11pt Times New Roman;margin:0'>G&amp;A Exp<BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:49.05pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2022</FONT></P>
</TD><TD valign=bottom style='width:35.9pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:51.9pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2021</FONT></P>
</TD><TD valign=bottom style='width:33.1pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:52.05pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2022</FONT></P>
</TD><TD valign=bottom style='width:37.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:51.7pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2021</FONT></P>
</TD><TD valign=bottom style=width:13.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:32.8pt><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:89.7pt><P style='font:11pt Times New Roman;margin:0'>IIA Amort - UK:</P>
</TD><TD valign=top style=width:49.05pt><P align=right style='font:11pt Times New Roman;margin:0'>$ &nbsp;467</P>
</TD><TD valign=top style='width:35.9pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> 3.4</P>
</TD><TD valign=top style='width:51.9pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$ &nbsp;536</P>
</TD><TD valign=top style='width:33.1pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;4.1</P>
</TD><TD valign=top style='width:52.05pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$ 1,965</P>
</TD><TD valign=top style='width:37.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;3.8</P>
</TD><TD valign=top style='width:51.7pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$2,189</P>
</TD><TD valign=top style=width:13.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:32.8pt><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;4.5</P>
</TD></TR>
<TR><TD valign=top style=width:89.7pt><P style='font:11pt Times New Roman;margin:0'>IIA Amort&#8211; CSI:</P>
</TD><TD valign=top style=width:49.05pt><P align=right style='font:11pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=top style='width:35.9pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>8.1</P>
</TD><TD valign=top style='width:51.9pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=top style='width:33.1pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;8.6</P>
</TD><TD valign=top style='width:52.05pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;4,421</P>
</TD><TD valign=top style='width:37.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;8.5</P>
</TD><TD valign=top style='width:51.7pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;4,421</P>
</TD><TD valign=top style=width:13.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:32.8pt><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;9.0</P>
</TD></TR>
<TR><TD valign=top style=width:89.7pt><P style='font:11pt Times New Roman;margin:0'>UK:</P>
</TD><TD valign=top style=width:49.05pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;145</P>
</TD><TD valign=top style='width:35.9pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:51.9pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;146</P>
</TD><TD valign=top style='width:33.1pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.05pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>573</P>
</TD><TD valign=top style='width:37.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:51.7pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;616</P>
</TD><TD valign=top style=width:13.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:32.8pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:89.7pt><P style='font:11pt Times New Roman;margin:0'>US:</P>
</TD><TD valign=top style=width:49.05pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;809</P>
</TD><TD valign=top style='width:35.9pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:51.9pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp; 545</P>
</TD><TD valign=top style='width:33.1pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.05pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;2,826</P>
</TD><TD valign=top style='width:37.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:51.7pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;2,208</P>
</TD><TD valign=top style=width:13.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:32.8pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:89.7pt><P style='font:11pt Times New Roman;margin:0'>IRE:</P>
</TD><TD valign=top style=width:49.05pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;94</P>
</TD><TD valign=top style='width:35.9pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:51.9pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp; &nbsp;86</P>
</TD><TD valign=top style='width:33.1pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.05pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;319</P>
</TD><TD valign=top style='width:37.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:51.7pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp; 321</P>
</TD><TD valign=top style=width:13.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:32.8pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:89.7pt><P style='font:11pt Times New Roman;margin:0'>AUS:</P>
</TD><TD valign=top style=width:49.05pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;42</P>
</TD><TD valign=top style='width:35.9pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:51.9pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>42</P>
</TD><TD valign=top style='width:33.1pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:52.05pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;166</P>
</TD><TD valign=top style='width:37.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:51.7pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp; 178</P>
</TD><TD valign=top style=width:13.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:32.8pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:89.7pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>CAN:</FONT></P>
</TD><TD valign=top style=width:49.05pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31</FONT></P>
</TD><TD valign=top style='width:35.9pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>&#160;&#160;&#160;&#160;&#160;&#160;&#160;</FONT></P>
</TD><TD valign=top style='width:51.9pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp; &nbsp;39</FONT></P>
</TD><TD valign=top style='width:33.1pt;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</FONT></P>
</TD><TD valign=top style='width:52.05pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>&#160;&#160;&#160;&#160;&#160;137</FONT></P>
</TD><TD valign=top style='width:37.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</FONT></P>
</TD><TD valign=top style='width:51.7pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;  164</FONT></P>
</TD><TD valign=top style=width:13.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:32.8pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</FONT></P>
</TD></TR>
<TR style=height:17.1pt><TD valign=top style=width:89.7pt><P style='font:11pt Times New Roman;margin:0'>Total G&amp;A:</P>
</TD><TD valign=top style=width:49.05pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;2,693</P>
</TD><TD valign=top style='width:35.9pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>19.8</P>
</TD><TD valign=top style='width:51.9pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>2,499</P>
</TD><TD valign=top style='width:33.1pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>19.3</P>
</TD><TD valign=top style='width:52.05pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>10,407</P>
</TD><TD valign=top style='width:37.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>19.9</P>
</TD><TD valign=top style='width:51.7pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> 10,097</P>
</TD><TD valign=top style=width:13.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:32.8pt><P align=center style='font:11pt Times New Roman;margin:0'>20.6</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>The table below identifies &#8220;constant currency&#8221; OUS G&amp;A expenses for 4Q and year 2022 compared to the same periods in 2021:</P>
<TABLE style=border-collapse:collapse;width:432.9pt><TR><TD valign=bottom style=width:86.4pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>G&amp;A Exp<BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'>4Q 2022<BR><FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style=width:36pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:52.4pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2021</FONT></P>
</TD><TD valign=bottom style='width:33.1pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2022<BR><FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style=width:33.1pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:52.4pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2021</FONT></P>
</TD><TD valign=bottom style=width:33.1pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:86.4pt><P style='font:11pt Times New Roman;margin:0'>IIA Amort- UK:</P>
</TD><TD valign=bottom style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'> $ 535</P>
</TD><TD valign=bottom style=width:36pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:52.4pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 535</P>
</TD><TD valign=bottom style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$2,187</P>
</TD><TD valign=bottom style=width:33.1pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:52.4pt><P align=right style='font:11pt Times New Roman;margin:0'>$2,189</P>
</TD><TD valign=top style=width:33.1pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:86.4pt><P style='font:11pt Times New Roman;margin:0'>Other&#8211; UK:</P>
</TD><TD valign=bottom style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;166</P>
</TD><TD valign=bottom style=width:36pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:52.4pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;146</P>
</TD><TD valign=bottom style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;642</P>
</TD><TD valign=bottom style=width:33.1pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:52.4pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;616</P>
</TD><TD valign=top style=width:33.1pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:86.4pt><P style='font:11pt Times New Roman;margin:0'>IRE:</P>
</TD><TD valign=bottom style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;106</P>
</TD><TD valign=bottom style=width:36pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:52.4pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;86</P>
</TD><TD valign=bottom style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;359</P>
</TD><TD valign=bottom style=width:33.1pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:52.4pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;321</P>
</TD><TD valign=top style=width:33.1pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:86.4pt><P style='font:11pt Times New Roman;margin:0'>AUS:</P>
</TD><TD valign=bottom style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;47</P>
</TD><TD valign=bottom style=width:36pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:52.4pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;42</P>
</TD><TD valign=bottom style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;180</P>
</TD><TD valign=bottom style=width:33.1pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:52.4pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;178</P>
</TD><TD valign=top style=width:33.1pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:86.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>CAN:</FONT></P>
</TD><TD valign=bottom style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;33</FONT></P>
</TD><TD valign=bottom style=width:36pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:52.4pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;39</FONT></P>
</TD><TD valign=bottom style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;142</FONT></P>
</TD><TD valign=bottom style=width:33.1pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:52.4pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;163</FONT></P>
</TD><TD valign=top style=width:33.1pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:86.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:36pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:52.4pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:33.1pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:52.4pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:33.1pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:12.15pt><TD valign=top style=width:86.4pt><P style='font:11pt Times New Roman;margin:0'>Total G&amp;A:</P>
</TD><TD valign=bottom style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;887</P>
</TD><TD valign=bottom style=width:36pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:52.4pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;848</P>
</TD><TD valign=bottom style='width:33.1pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:52.4pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;3,510</P>
</TD><TD valign=bottom style=width:33.1pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:52.4pt><P align=right style='font:11pt Times New Roman;margin:0'>3,467</P>
</TD><TD valign=top style=width:33.1pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:4pt;margin-bottom:0pt'>Product development (R&amp;D) expenses declined as a result of reassigning engineers to help with manufacturing improvements and quality assurance in a challenging year. </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>In summary, despite inflationary cost pressures, in 2022 UTMD was able to improve OI close to 5% when GP increased just 4%.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Income Before Tax (EBT)</FONT> </P>
<P style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:6pt'>EBT results from subtracting net non-operating expense (NOE) or adding net non-operating income (NOI) from or to, as applicable, OI. &nbsp;Consolidated 4Q 2022 EBT was $5,591 (41.2% of sales) compared to $5,181 (40.1% of sales) in 4Q 2021, an increase of 7.9%. Consolidated 2022 EBT was $20,659 (39.5% of sales) compared to $19,061 (38.9% of sales) in 2021, an increase of 8.4%. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) income from rent of underutilized property, investment income and royalties received from licensing the Company&#8217;s technology. Negative NOE is NOI. &nbsp;Net NOI in 4Q 2022 was $521 compared to $51 NOI in 4Q 2021. Net NOI in 2022 was $869 compared to $181 NOI in 2021. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The increase in 4Q 2022 and year 2022 NOI was due primarily to higher interest rates for higher cash balances. &nbsp;It is interesting to note that the higher NOI covered the increase in litigation expenses in G&amp;A OE.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 4Q 2022 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense (&#8220;adjusted consolidated EBITDA&#8221;) was $7,404 compared to $7,035 in 4Q 2021, an increase of 5.2% in this 4Q operating metric. Adjusted consolidated EBITDA was $27,891 for the year 2022 compared to $26,530 in 2021, an increase of 5.1% in this annual operating metric. &nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales was 54.5% in both 4Q 2022 and 4Q 2021. UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales was 53.3% for the year 2022 compared to 54.1% in 2021. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Management believes that this operating performance metric provides meaningful supplemental information to both management and investors and confirms UTMD&#8217;s ongoing excellent financial performance. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number:</P>
<TABLE style=border-collapse:collapse;width:549pt;margin-left:5.4pt><TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2022</FONT></P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2021</FONT></P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> 2022</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> 2021</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>EBT</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>$5,591</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$5,181</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$20,659</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>$19,061</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Depreciation Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>158</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>153</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>612</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>636</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Femcare IIA Amortization Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>467</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>535</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,965</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>2,189</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>CSI IIA Amortization Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>4,421</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>4,421</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Other Non-Cash Amortization Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'> 8</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>8</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>31</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>35</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Stock Option Compensation Expense</P>
<P style='font:11pt Times New Roman;margin:0'>Interest Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>62</P>
<P align=right style='font:11pt Times New Roman;margin:0'>- </P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>43</P>
<P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>183</P>
<P align=right style='font:11pt Times New Roman;margin:0'>- </P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>166</P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-left:36pt'>-</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:207pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Remeasured Foreign Currency Balances</P>
</TD><TD valign=top style='width:49.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>13</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>10</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>20</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>22</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:207pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>UTMD non-US GAAP EBITDA:</P>
</TD><TD valign=top style='width:49.5pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$7,404</P>
</TD><TD valign=top style='width:58.5pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$7,035</P>
</TD><TD valign=top style='width:58.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$27,891</P>
</TD><TD valign=top style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$26,530</P>
</TD><TD valign=top style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Note</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>All UTMD income statement measures from GP through EBT including non-US GAAP adjusted consolidated EBITDA for 2021 were unaffected by the change in the UK corporate income tax rate enacted in 2Q 2021.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Net Income (NI)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>NI in 4Q 2022 of $4,555 (33.6% of sales) was 10.3% higher than NI of $4,131 (32.0% of sales) in 4Q 2021. NI for the year 2022 of $16,473 (31.5% of sales) was 11.4% higher than the US GAAP NI of $14,788 (30.1% of sales) in 2021. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>NI per US GAAP in the prior year of 2021 was affected by an additional tax provision expense required to be recorded in the quarter in which a tax change is enacted, as a result of an adjustment to UTMD&#8217;s deferred tax liability (DTL). &nbsp;This lowered 2021 NI by $390. &nbsp;The DTL results from the tax effect of not being able to deduct remaining future amortization expense of Femcare IIA. In 2Q 2021, because the UK reset its corporate tax rate from 19% to 25% beginning with 2Q 2023, it caused UTMD to have to book an additional $390 in its 2Q 2021 income tax provision that represents the additional tax which will be paid in the UK over the then remaining five year life of the 2011 Femcare acquisition IIA. Excluding the $390 DTL increase in 2Q 2021, year 2021 non-US GAAP NI was $15,178 (30.9% of sales). &nbsp;A comparison of 2022 NI with non-US GAAP 2021 NI gives an 8.5% increase (instead of 11.4%), which is more consistent with the change in EBT. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The average consolidated income tax provisions (as a % of the same period EBT) in 4Q 2022 and 4Q 2021 were 18.5% and 20.3% respectively, and were 20.3% and 22.4% in year 2022 and 2021 respectively. As the income tax provision rate for 2021 is not directly related to EBT because of the DTL adjustment, UTMD provides the following non-US GAAP income tax rate excluding the 2Q 2021 $390 tax provision adjustment: 20.4%, which is more consistent with 2022. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The consolidated income tax provision rate varies as the mix in taxable income among U.S. and foreign subsidiaries with differing income tax rates differs from period to period. UTMD has consistently paid millions of dollars in income taxes annually. The basic 2022 corporate income tax rates in each of the sovereignties were the same as in the prior year. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Earnings per share (EPS)</FONT>. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Diluted EPS in 4Q 2022 were $1.253 compared to $1.127 in 4Q 2021, an 11.2% increase. &nbsp;US GAAP diluted EPS in year 2022 were $4.522 compared to $4.041 in 2021, an 11.9% increase. &nbsp;Excluding the &#8220;one-time&#8221; income tax provision increases due to the DTL adjustment in 2021, non-US GAAP diluted EPS in 2021 were $4.147. The 2022 EPS increase over the non-US GAAP 2021 EPS was 9.0%, which is more indicative of normal operating results. The increases in EPS were higher than the increases in OI as a result of the 2022 improvement in NOI from higher interest on higher cash balances, and a stock buy-back in 2Q 2022. Diluted shares were 3,634,686 in 4Q 2022 compared to 3,667,199 in 4Q 2021, and 3,643,256 for the year 2022 compared to 3,659,814 in 2021. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The number of shares used for calculating 4Q 2022 and year 2022 EPS were higher than the December 31, 2022 outstanding shares balance because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee options. Outstanding shares at the end of calendar year 2022 were 3,627,767 compared to 3,654,737 at the end of 2021. The difference was due to 3,501 shares in employee option exercises during 2022, less 366 shares swapped to pay the exercise price. For comparison, outstanding shares were 3,625,195 at the end of 3Q 2022. The total number of outstanding unexercised employee and outside director options at December 31, 2022 was 67,433 at an average exercise price of $73.66, including shares awarded but not yet vested. This compares to 51,858 unexercised option shares at the end of 2021 at an average exercise price of $69.24/ share, including shares awarded but not vested. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The number of shares added as a dilution factor for 4Q 2022 was 7,630 compared to 15,132 in 4Q 2021. The number of shares added as a dilution factor for the year 2022 was 5,934 compared to 12,606 in 2021. In October 2022, 20,600 option shares were awarded to 40 employees at an exercise price of $82.60 per share. No options were awarded in 2021. UTMD&#8217;s stock option plan, approved by stockholders to provide an ownership stake in the Company, continues to be an integral part of attracting and retaining productive employees. &nbsp;Employees average 15 years tenure with the Company, which is a key strategic </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style=font-size:11pt>benefit. &nbsp;The plan has not been dilutive to stockholders, as the Company has consistently repurchased more shares in the open market than it awarded in options.</FONT></P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD paid $1,051 ($0.290/share) in dividends to stockholders in 4Q 2022 compared to $8,349 ($2.285/ share) paid in 4Q 2021. The dividends paid in 4Q 2021 included a regular $0.285/share dividend declared in September after 3Q 2021, and a special $2.00/ share dividend declared in November and paid in December in lieu of a regular dividend that otherwise would have been paid in January 2022. Without having been able to repurchase its shares in 2021, the special dividend helped the Company continue to achieve its continuing capital allocation objective of returning value to stockholders. UTMD paid $3,162 ($0.87/share) in dividends to stockholders in 2022 compared to $11,465 ($3.14/ share) in dividends in 2021. The dividends paid in 2022 represented three calendar quarters because of the early dividend payment in 2021. Also, in 2022 UTMD made $2,495 in share repurchases. As declared in November 2022, UTMD&#8217;s regular quarterly dividend was increased to $0.295 per share starting with a January 2023 payment. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>In 2Q 2022, UTMD repurchased 30,105 of its shares in the open market at $82.88/ share. No shares were repurchased in 2021. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. UTMD&#8217;s closing share price at the end of 2022 was $100.53, up 0.5% from the closing price of $100.00 at the end of 2021, and up 17.8% from the end of the prior calendar quarter. In comparison, the major stock market indices were all down for the year 2022: the Dow Jones Industrial Average down 8.8%, The S&amp;P 500 Index down 19.4% and the NASDAQ in which UTMD shares are traded down 33.1%. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Balance Sheet</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>Please see the audited December 31, 2022 Balance Sheet at the end of this report. At the end of 2022 compared to the end of 2021, UTMD&#8217;s cash and investments increased $14.1 million to $75.1 million as a result of $27.9 million operating EBITDA minus income taxes, $5.7 million in stock repurchases and cash dividends paid to stockholders, and a $0.7 million increase in non-cash working capital as a result of higher sales and production activity, including a $2.2 million increase in inventories as a hedge against supply chain disruptions. At December 31, 2022, Net Intangible Assets decreased to 18.8% of total consolidated assets from 27.2% on December 31, 2021. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Financial ratios as of December 31, 2022 which may be of interest to stockholders follow:</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>Current Ratio = 15.6&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>Days in Trade Receivables (based on 4Q 2022 sales activity) = 36.7&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Average Inventory Turns in 2022 (based on 2022 CGS) = 2.6&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>4)</KBD>2022 ROE (before dividends) = 15%&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. &nbsp;Risk factors that could cause results to differ materially from those projected include global economic conditions, market acceptance of products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare in general, tax reforms, the Company&#8217;s ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD&#8217;s public disclosure filings with the SEC. &nbsp;UTMD&#8217;s 2022 SEC Form 10-K will be filed on or before March 31, 2023, and can be accessed on <FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><I>www.utahmed.com</I></FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long term outcomes for their patients. &nbsp;For more information about Utah Medical Products, Inc., visit UTMD&#8217;s website at<B><I> </I></B><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><I>www.utahmed.com</I></FONT>.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-size:13pt><B>Utah Medical Products, Inc.</B></FONT></P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>INCOME STATEMENT, Fourth Quarter (three months ended December 31)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share):</P>
<TABLE style=border-collapse:collapse;width:517.2pt><TR><TD valign=top style=width:149.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2022</FONT></P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4Q 2021</FONT></P>
</TD><TD valign=top style=width:73.65pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 13,575</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$12,914</P>
</TD><TD valign=top style=width:73.65pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;5.1%</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>8,327</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>8,112</P>
</TD><TD valign=top style=width:73.65pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;2.6%</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>5,070</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>5,129</P>
</TD><TD valign=top style=width:73.65pt><P align=center style='font:10pt Times New Roman;margin:0'> ( 1.2%)</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>5,591</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>5,181</P>
</TD><TD valign=top style=width:73.65pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;7.9%</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt Times New Roman;margin:0'>Net Income (US GAAP)</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>4,555</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>4,131</P>
</TD><TD valign=top style=width:73.65pt><P align=center style='font:10pt Times New Roman;margin:0'>10.3%</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt Times New Roman;margin:0'>Diluted EPS (US GAAP)</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$1.253</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$1.127</P>
</TD><TD valign=top style=width:73.65pt><P align=center style='font:10pt Times New Roman;margin:0'>11.2%</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:149.4pt><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>3,635</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>3,667</P>
</TD><TD valign=top style=width:73.65pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>INCOME STATEMENT, Twelve Months (Calendar Year ended December 31)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share): </P>
<TABLE style=border-collapse:collapse;width:519.75pt><TR><TD valign=top style=width:144.9pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2022</FONT></P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2021</FONT></P>
</TD><TD valign=top style=width:69.75pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD><TD valign=top style=width:83.25pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 52,281</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 49,054</P>
</TD><TD valign=top style=width:69.75pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;6.6%</P>
</TD><TD valign=top style=width:83.25pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>32,196</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>30,917</P>
</TD><TD valign=top style=width:69.75pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;4.1%</P>
</TD><TD valign=top style=width:83.25pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:144.9pt><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>19,790</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>18,880</P>
</TD><TD valign=top style=width:69.75pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;4.8%</P>
</TD><TD valign=top style=width:83.25pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:144.9pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style='width:73.35pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>20,659</P>
</TD><TD valign=top style='width:72pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>19,061</P>
</TD><TD valign=top style='width:69.75pt;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;8.4%</P>
</TD><TD valign=top style='width:83.25pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:76.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:144.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><I>Net Income before DTL adjust</I></P>
<P style='font:10pt Times New Roman;margin:0'>Net Income (US GAAP)</P>
</TD><TD valign=top style='width:73.35pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'><I>16,473</I></P>
<P align=right style='font:10pt Times New Roman;margin:0'>16,473</P>
</TD><TD valign=top style='width:72pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'><I>15,178</I></P>
<P align=right style='font:10pt Times New Roman;margin:0'>14,788</P>
</TD><TD valign=top style='width:69.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><I> &nbsp;8.5%</I></P>
<P align=center style='font:10pt Times New Roman;margin:0'>11.4%</P>
</TD><TD valign=top style='width:83.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:76.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:144.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><I>Diluted EPS before DTL adjust</I></P>
<P style='font:10pt Times New Roman;margin:0'>Diluted EPS (US GAAP)</P>
</TD><TD valign=top style='width:73.35pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'><I>$ 4.522</I></P>
<P align=right style='font:10pt Times New Roman;margin:0'>$ 4.522</P>
</TD><TD valign=top style='width:72pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'><I>$ 4.147</I></P>
<P align=right style='font:10pt Times New Roman;margin:0'>$ 4.041</P>
</TD><TD valign=top style='width:69.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><I> &nbsp;9.0%</I></P>
<P align=center style='font:10pt Times New Roman;margin:0'>11.9%</P>
</TD><TD valign=top style='width:83.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:76.5pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:144.9pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top style='width:73.35pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,643</P>
</TD><TD valign=top style='width:72pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,660</P>
</TD><TD valign=top style='width:69.75pt;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:83.25pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:76.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0pt'>BALANCE SHEET</KBD><KBD style=margin-left:252pt></KBD> &nbsp;</P>
<TABLE style=border-collapse:collapse><TR style=height:21.6pt><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>(in thousands)</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>(audited) &nbsp;</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2022</FONT></P>
</TD><TD valign=top style=width:90pt><P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(unaudited) &nbsp;</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>SEP 30, 2022</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>(audited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2021</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Assets</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:9.9pt><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Cash &amp; Investments</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>$75,052</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>$69,511</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$60,974</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Accounts &amp; Other Receivables, Net</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>5,538</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>6,034</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>5,132</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Inventories</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>8,814</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>8,310</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>6,596</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Other Current Assets</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>515</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>387</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>456</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>89,919</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>84,242</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>73,158</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>Property &amp; Equipment, Net</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>10,619</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>10,257</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>11,067</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>Intangible Assets, Net</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>23,336</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>23,914</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>31,411</FONT></P>
</TD></TR>
<TR style=height:21.15pt><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>$123,874</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>$118,413</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$115,636</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Liabilities &amp; Stockholders&#8217; Equity</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>Accounts Payable</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;&nbsp;&nbsp;1,218</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;1,289</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;&nbsp;760</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>REPAT Tax Payable</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>432</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>220</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>220</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>Other Accrued Liabilities</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4,103</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4,760</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2,765</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Total Current Liabilities</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$5,753</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$6,269</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$3,745</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>Deferred Tax Liability &#8211;&nbsp;Intangible Assets</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>1,513</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>1,479</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>2,105</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>Long Term Lease Liability </P>
<P style='font:10pt Times New Roman;margin:0'>Long Term REPAT Tax Payable</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>341</P>
<P align=right style='font:10pt Times New Roman;margin:0'>1,463</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>354</P>
<P align=right style='font:10pt Times New Roman;margin:0'>1,675</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>396</P>
<P align=right style='font:10pt Times New Roman;margin:0'>1,675</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>Deferred Revenue and Income Taxes</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>549</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>450</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>577</P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'>Stockholders&#8217; Equity</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>114,255</FONT></P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>108,186</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>107,138</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:185.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities &amp; Stockholders&#8217; Equity</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>$123,874</P>
</TD><TD valign=top style=width:90pt><P align=right style='font:10pt Times New Roman;margin:0'>$118,413</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$115,636</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>utmd-20230131_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK5GW761L0VGXA5UT0]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20230131"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20230131.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>utmd-20230131_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK5GW761L0VGXA5UT0]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20230131"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SEC Form</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Exchange</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementTenderOffer' xlink:to='lab_dei_PreCommencementTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SolicitingMaterial' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Soliciting Material</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SolicitingMaterial' xlink:to='lab_dei_SolicitingMaterial'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current with reporting</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax Identification Number (TIN)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant CIK</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fiscal Year End</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_WrittenCommunications' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Written Communications</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_WrittenCommunications' xlink:to='lab_dei_WrittenCommunications'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Period End date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common stock shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementIssuerTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Issuer Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementIssuerTenderOffer' xlink:to='lab_dei_PreCommencementIssuerTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>utmd-20230131_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK5GW761L0VGXA5UT0]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20230131"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20230131.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_WrittenCommunications' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SolicitingMaterial' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementTenderOffer' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementIssuerTenderOffer' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='33.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>utmd-20230131.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK5GW761L0VGXA5UT0]. www.edgarsuite.com -->
<schema xmlns='http://www.w3.org/2001/XMLSchema' xmlns:us-gaap='http://fasb.org/us-gaap/2022' xmlns:fil='http://utahmed.com/20230131' xmlns:dei='http://xbrl.sec.gov/dei/2022' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' targetNamespace='http://utahmed.com/20230131' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xbrli='http://www.xbrl.org/2003/instance' elementFormDefault='qualified' attributeFormDefault='unqualified'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230131_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230131_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230131_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import namespace='http://xbrl.sec.gov/dei/2022' schemaLocation='https://xbrl.sec.gov/dei/2022/dei-2022.xsd'/>
	<import namespace='http://fasb.org/us-gaap/2022' schemaLocation='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd'/>
	<import namespace='http://fasb.org/us-gaap-sup/2022q3' schemaLocation='https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd'/>
	<import namespace='http://www.xbrl.org/dtr/type/2020-01-21' schemaLocation='https://www.xbrl.org/dtr/type/2020-01-21/types.xsd'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139945757296096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Registrant CIK</a></td>
<td class="text">0000706698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">SEC Form</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Period End date</a></td>
<td class="text">Jan. 31,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Tax Identification Number (TIN)</a></td>
<td class="text">87-0342734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-12575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>utmd-20230131_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20230131.xsd" xlink:type="simple"/>
    <context id="D230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="D230131" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="D230131" id="fact2">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="D230131">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="D230131">2023-01-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="D230131">UTAH MEDICAL PRODUCTS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D230131">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="D230131">000-12575</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="D230131">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D230131">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D230131">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D230131">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D230131">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D230131">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D230131">566-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="D230131">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="D230131">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="D230131">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="D230131">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="D230131">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M]X(_5MS;1^+C P  EPX  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RE
MEVMOXC@4AO^*E956NU+;7 B7=@")TG:&F5Y0H5-IO[F) 6L<.V.;TO[[/0Z0
ML#/AI-+R@=B)S^O'Q_:;N+]1^H=9,6;)6R:D&7@K:_,+WS?)BF74G*F<27BR
M4#JC%JIZZ9M<,YH609GPHR#H^!GETAOVBWM3/>RKM15<LJDF9IUE5+]?,J$V
M R_T]C<>^7)EW0U_V,_IDLV8?<JG&FI^J9+RC$G#E22:+0;>*+RXC(J HL5W
MSC;FH$S<4%Z4^N$JDW3@!8Z("998)T'A\LK&3 BG!!P_=Z)>V:<+/"SOU6^*
MP<-@7JAA8R6>>6I7 Z_GD90MZ%K81[7YPG8#:CN]1 E3_)/-MFT<>R19&ZNR
M73 09%QNK_1MEXB#@*AW)"#:!40%][:C@O**6CKL:[4AVK4&-5<HAEI$ QR7
M;E9F5L-3#G%V>*62-239$BI3<BTMM^]D(K>S#5GK^Q8Z<4W]9"=XN16,C@A^
MI?*,M,(3$@51Z[_A/K"5@%$)&!5ZK6. S%(N3!W(-C"N#W3+^<+D-&$##]:K
M8?J5><,__P@[P2<$JU5BM3#UX2-;<F,UA<R-)]_JZ/#X '[=H-,Y[R$P<0D3
M?Q3FGF:LC@87>)J/OI"[ZZO)>'1+IH\/5T_C^>R$3.['9PA>N\1KH^JSZS%Q
M6ZB."X_LG7Y#^N^4_7=0E2G37+G5G9*4VMKTX +EFFY:U-V2J(L*SND;F:2P
M[?B")\5&(_?K[(5I\M=\<O]W'2$NV.N>!JTXZK9BA*Y7TO50L>N,Z2672_(9
M NV*C%664_E>1X4++:@P# $Z+X'.<:"]+R5*YTH7"3LA,PN3290&OK6T^AVN
M:>WDXN)/<X0P#"H?#3[">,,%V\UEK7?B(F *IV'4[K8QI -K#S^"-$I3\#]S
MLB^06VA''F1MKAHDNT'<(C-XNZ](*PC(,S,60ZU,/D3-^C?4L:O!U,[5IOX=
MA,O=\?25"FSIA971A[A3_XI6+KNI5J]<)O5IQ#7Q-5?9?HC;]J]H4V4L%>0?
MGA_="PV*O3B(NQA;Y?DA;MW%#([@0_$X2H/W!R$&4IE_B)OWK4H@)].5DNC&
MQ$7:G0YLS"# B"KS#W&S?M;<6B:=KV9KN7L!U'[A- @U^6M8.7Z(._5,"9YP
MZTS_#I:WYE34\OP_OP\KPP]Q4YYJ=II >ACLK^+S=,YD"J_'A\7BR/SA>DUD
M4>7S$6[1OY%-C%D#61-@@VPC8.7Z$6[1(Z!*"[(;09>U*+C 413_X)CACFQW
MU'TF&"+8 H2"LRYL:+T]!6TK5N7%R>-%63C'%,45G!R9=@W@^4(INZ^XPTQY
M%AW^"U!+ P04    " #W@C]6GZ ;\+$"  #B#   #0   'AL+W-T>6QE<RYX
M;6S=5VUKVS 0_BM"/V!N8FKBD1BV0&&PC4+S85^56'8$>O%DN7/ZZZ>S;"=I
M=67=A['-H<G=/;J[1W<GF:Y;=Y+\X<BY([V2NMW0HW/-^R1I#T>N6/O.-%Q[
MI#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4
M!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K <XRBA
MC05C$C*$[_VX_!DP::U7A90SP24-AF+=,.>XU7=>&18/QA<0&>7=J?$,:\M.
MB^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4
M?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&
M?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQ
MY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7
M^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJ
MOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD<VWL,\E=,E[7FY'U=;[
M021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#S"=X87G^I_VLT/T$#..VBB(KU&>%
M^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%N
MXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"
M5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;  4/2
M='@//GL?)=-[*CG_5U/\!%!+ P04    " #W@C]6EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( />"/U8<.&7J/P$
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M?P%02P$"% ,4    " #W@C]6!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( />"/U9Y/DF<[0   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( />"/U:97)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ ]X(_5MS;1^+C P  EPX  !@
M         ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( />"/U:?H!OPL0(  .(,   -              "  24,  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ ]X(_5I>*NQS     $P(   L
M ( ! 0\  %]R96QS+RYR96QS4$L! A0#%     @ ]X(_5APX9>H_ 0  / (
M  \              ( !Z@\  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M />"/U8D'INBK0   /@!   :              "  581  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( />"/U9ED'F2&0$  ,\#   3
M              "  3L2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )
-  D /@(  (43      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="utmd-20230131.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="utmd-20230131.htm">utmd-20230131.htm</File>
    <File>utmd-20230131.xsd</File>
    <File>utmd-20230131_def.xml</File>
    <File>utmd-20230131_lab.xml</File>
    <File>utmd-20230131_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "utmd-20230131.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 19
   },
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "utmd-20230131_def.xml"
     ]
    },
    "inline": {
     "local": [
      "utmd-20230131.htm"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20230131_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20230131_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "utmd-20230131.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 34,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 19,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "fil",
   "nsuri": "http://utahmed.com/20230131",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230131.htm",
      "contextRef": "D230131",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230131.htm",
      "contextRef": "D230131",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Fiscal Year End"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Period End date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "SEC Form"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Registrant CIK"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Number of common stock shares outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Current with reporting"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Tax Identification Number (TIN)"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Voluntary filer"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Trading Exchange"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://utahmed.com/20230131/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001096906-23-000240-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001096906-23-000240-xbrl.zip
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MW_!85Y6+V4"=#KFK^N7\\4F@4I6S?CBN:(L08)3-TSY#?8:'N*9Y&H,H6_E
M$1/_ "_.@G&[+F 6EW7X@$G29$/2$@/JC]N9IXBY03W>\\L.T(R%T+%=N6LV
M.O4+TNY4._4V.<O8E;-, ,A_.V2P#W>M1J<!8*O-"U+_4ONUVOQ8)[6;Z^M&
MN]VX:2[LK;!^;Y^I[(,I4L(_(A=IL%0_?[".S=.L6<B7MM9/#/-94-:Z*,N
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ML?-L>F.=[-"'1I*N<+1>KL'0DZ)AYO+9(LX,5E' '?7\!]H4X61(P"0H)'_
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MZ+CI/J'7E]JV\+@#O/)[UV![P !YW[G(3@=$!LF(GLJKE:<0W\V([-RFZ8G
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MSS3Y+29[_/_?%^=_WNZX]+1A0'O,L$-&OQJT"R:B3+TA'<G3QP!ST+E-G:_
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MQFN-?T8\3&+Y55/6SRQ2NI$W(@Z-<&%Q-BD?)Y@EX  %(KZ_T&9]ZG4QT8R
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MZ=8.1CM1"U6K,^P%Y@D# $$97#4Q)Z!@ A6J#GI*4J'.%25?>,_93YM_$;B
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MRZ-,V!@0%&B9ZO OV:"%Z)*C_Y5^Y3=02P,$%     @ ]X(_5HI4FRLK"
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M<N(J)X-D3$EX23G:++[LFEH0+YD"ZIJ6*\*7A&+1TVOXE NXABRK:D%YPQC
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M,#(S,#$S,2YX<V102P$"% ,4    " #W@C]69U$]R1<"   F!P  %0
M        @ %]$0  =71M9"TR,#(S,#$S,5]D968N>&UL4$L! A0#%     @
M]X(_5HI4FRLK"   TDX  !4              ( !QQ,  '5T;60M,C R,S Q
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( />"/U:@F9LZJ04  $8T   5
M      "  24<  !U=&UD+3(P,C,P,3,Q7W!R92YX;6Q02P4&      4 !0!'
) 0   2(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
